"The COVID pandemic has highlighted the need to increase vaccination in Africa"
Signature(s)
Amount (.*)
€ 4,750,000
Sector(s)
Industry
: € 4,750,000
Signature date(s)
8/07/2021 : € 4,750,000
Link to source
Data sheet
Other links
News & Stories
Link to source
Other links
Inside the project
How and Why
Accessible health products and vaccines produced in Africa
Why
- Fewer than 2% of the three billion vaccine doses administered globally have been in Africa
- New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines
- The COVID-19 pandemic highlighted the need to increase vaccination in Africa
How
- The vaccine production facility at the Institut Pasteur de Dakar plans to produce as many as 25 million doses of an approved COVID-19 vaccine a month by the end of 2022
- Improve investment in Africa’s health sector and boost the production and accessibility of heath products and technologies
- Support technology transfer and the creation of regional vaccine manufacturing hubs in other regions of Africa
Sectors & Countries
Story
A COVID-19 vaccine of its own for Africa
To increase vaccination rates, Africa needs to secure more doses. New manufacturing facilities on the continent are essential, as Africa currently imports 99% of its vaccines. The new vaccine production facility at the Institut Pasteur de Dakar is a key link in a vaccine strategy developed by the African Union and the Africa Centres for Disease Control and Prevention.
“Not only does this reinforce the health system, but also through this particular project it will create jobs, develop capacities in terms of knowhow and workforce, while bringing in new technology,” says Sall.
"It’s very important that we have this solidarity between African countries and European countries because it helps to build up a global ecosystem for global health security."
Related media
Health Solutions: Searching for the magic pills
Vaccines get all the attention, but COVID treatments for people who get sick are just as important to end this pandemic
Health Solutions: Why risky ideas are good in a crisis
To end the pandemic and avoid future problems, we must stop being afraid of risk and start innovating in COVID vaccines and all types of other research
A COVID-19 vaccine of its own for Africa
Europe backs COVID-19 vaccine production in Africa with an investment in Senegal’s Institut Pasteur de Dakar.
What’s the impact of an impact investment?
A study supported by the EU bank examines how an impact investment is contributing to improved maternal health services for Senegalese women
Links
Related projects and stories
Complaint Mechanism Policy renewal
The EIB Group is upgrading its independent Complaint Mechanism policy, following an external review and alignment with best practices of peer institutions. The proposed policy, submitted for a public consultation, foresees a more efficient handling of complaints, enhanced use of the Dispute Resolution mechanism to solve conflicts between project promoters and affected people, and other improvements. The draft policy focuses on alleged environmental and social impacts of the projects we finance and access to information about them, as part of our commitment to transparency, integrity and accountability.
EIB Advisory and the European Commission support EU Ports Strategy through new capacity building programme for small and medium sized ports
The European Investment Bank (EIB), through its advisory arm, and the European Commission are launching a new technical training programme under the JASPERS mandate, making a concrete step in strengthening EU’s strategic port infrastructure. The assignment is supported under a EC-EIB Joint Contribution Agreement providing financial backing from the Connecting Europe Facility and Cohesion Policy Funds.
Green rooftops cut energy costs and cool Serbian cities
Green rooftops and walls in Serbia are improving energy efficiency, cooling cities and helping residents live more comfortably with climate change.